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Context:Cholecystokinin (CCK)andneurotensinare stimulatedduringmeal intakeby thepresence
of fat in the small intestine. The sequence of events suggests that fat hydrolysis is crucial for
triggering the release.
Objective: The aim of this study was to investigate whether CCK mediated the effect of intraduo-
denal (ID) fat on neurotensin secretion via CCK-1 receptors.
Setting: This was a single center study; 34 male volunteers were studied in consecutive, random-
ized, double-blind, cross-over studies.
Subjects and Methods: CCK and neurotensin release were quantified in: 1) 12 subjects receiving
an ID fat infusionwithorwithout 60mgorlistat, an irreversible inhibitorofgastrointestinal lipases,
in comparison to vehicle; 2) 12 subjects receiving ID long chain fatty acids (C18s), ID medium chain
fatty acids, or ID vehicle; and 3) 10 subjects receiving ID C18 with and without the CCK-1 receptor
antagonist dexloxiglumide or ID vehicle plus iv saline (placebo). Hormone concentrations were
measured by specific RIA systems.
Results: ID fat induced a significant increase in CCK and neurotensin concentrations (P  0.001–
0.002). Inhibition of fat hydrolysis by orlistat abolished both effects. C18 stimulated CCK and
neurotensin release (P  0.001, respectively), whereas medium chain fatty acid was ineffective.
Dexloxiglumide administration partially blocked the effect of C18 on neurotensin; the effect was
only present in the first phase of neurotensin secretion.
Conclusions: Generation of C18 through hydrolysis of fat is a critical step for fat-induced stimu-
lationofneurotensin inhumans; the signal is in partmediated viaCCK release andCCK-1 receptors.
(J Clin Endocrinol Metab 93: 1964–1970, 2008)
Neurotensin is a gastrointestinal peptide stored in specificendocrine cells (N cells) of the distal small intestine; the
peptide has been implicated in the regulation of gastrointestinal
functions (1–3). Fat ingestion induces a dose-related increase in
neurotensin plasma concentrations, whereas glucose and amino
acidsproduceonlyminorornoeffect (4–6).Majorphysiological
functions of neurotensin include the stimulation of pancreatic
exocrine secretion, inhibition of gastric acid secretion, and in-
hibition of gastroduodenal motility (7–10). Intracerebroventric-
ular injections of neurotensin induce a dose-dependent inhibi-
tion of food intake in rats (11). The effect of peripheral
administration of neurotensin on food intake has not been in-
vestigated. Therefore, the role of neurotensin in regulating ap-
petite is not clear yet.
Several gut hormones have been implicated in the physiolog-
ical control of appetite or food intake with consequences for
conditions such as obesity or anorexia. A recent review summa-
rized the changes observed in fasting concentrations of gut hor-
mones in obese persons; the following changes were document-
ed: increased levels of cholecystokinin (CCK), insulin, and
amylin; and decreased concentrations of ghrelin, pancreatic
polypeptide, peptide YY (PYY), and glucagon-like peptide
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(GLP)-1 (12, 13). Interestingly, in obese human subjects, lower
neurotensin levels have been observed compared with lean con-
trols (14). More important, after gastric banding and bypass
procedures, respectively, neurotensin levels are increased (15,
16). Plasmaneurotensin levels showamorepronounced increase
after gastric bypass compared with gastric banding (15), sug-
gesting that specific bariatric surgical procedures result in dis-
tinct alterations of gastrointestinal hormone metabolism. The
fact that weight loss after gastric bypass surgery is associated
with increased circulating levels of neurotensin can be inter-
preted as evidence that increased neurotensin levels are mecha-
nistically linked to reduced appetite and weight after bariatric
surgery. Therefore, it is important to understand the physiolog-
ical factors controlling neurotensin release.
As mentioned before, fat is the most potent stimulus for the
release of neurotensin (4, 5); moreover, products of fat digestion
have been implicated in stimulating the release of various other
peptides, which have been associated with inhibition of food
intake (CCK,GLP-1, and PYY) (17–19). In fact, fat hydrolysis is
crucial for stimulatingCCKand PYY release (19). Therefore, we
were interested in investigatingwhether fat hydrolysis is essential
for stimulating neurotensin release; we were also interested in
testing whether the effect of hydrolyzed fat on neurotensin se-
cretion is mediated by CCK release via CCK-1 receptors. There-
fore, the aim of this study was to investigate whether CCK me-
diated the effect of intraduodenal (ID) fat on neurotensin
secretion via CCK-1 receptors.
Subjects and Methods
Subjects
A total of 34 male subjects, aged 20–30 yr (mean 25.2), partici-
pated in the study. The body weight of all subjects was within the
normal range for age, sex, and height. Each subject gave written
informed consent for the study. The human ethics committee of the
University Hospital, Basel, approved the protocol. Before acceptance,
each participantwas required to complete amedical interview, receive
a full physical examination, and participate in an initial laboratory
screening. No subject was receiving any medications, or had a history
of food allergies or dietary restrictions.
Experimental procedures
Part 1: effect of orlistat dissolved inoliveoil onneurotensin
release
Three treatments, separated by at least 7 d, were performed in 12
subjects in a randomized order. On the evening preceding each treat-
ment, subjects swalloweda radioopaquepolyvinyl feeding tube (external
diameter 8 French), which had an opening at the tip of the tube. The tube
was inserted through the nose because this procedure allowed the tube
to be retained overnight and for the duration of the experiment. The
position of the tube was located fluoroscopically, and the tip of the tube
was positioned in part III of the duodenum (100-cmdistal to the teeth).
It was firmly attached to the skin behind the ear to prevent further pro-
gression of the tube during the experiment.
The treatments were identical in design except for the ID infusions.
One treatment consisted of ID saline infusion for the duration of the
experiment (120min). In the second and third experiments, ID fat (olive
FIG. 1. Plasma concentrations of CCK (A) and neurotensin (B) during ID
infusions of triglycerides with or without the lipase inhibitor orlistat (30
mg/h) or infusion of vehicle (control treatment) in 12 healthy male
subjects. Triglycerides infused to the duodenum induced a treatment 
time interaction for CCK and neurotensin (P  0.01 each). CCK and
neurotensin increased progressively during triglyceride infusion.
Inhibition of fat hydrolysis completely abolished these effects. Plasma CCK
and neurotensin concentrations were not different from control values.
Data are mean  SEM.











Details of the assay have been previously described (19, 20).
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oil) with or without 60mg orlistat was used instead of saline throughout
the experiments. An infusion rate of 0.5 ml/min oil was chosen for the
duration of the experiment; this rate was taken from previous experi-
ments (19). The ID fat infusion solution was indistinguishable in ap-
pearance from the control solution (saline). The treatmentswere given in
a double-blind manner. During the experiments, samples of blood (7.5
ml each) were drawn at regular intervals into ice-chilled EDTA coated
tubes containing aprotinin (1000 kallikrein inhibiting unit/ml blood) for
plasma CCK and neurotensin determinations. Samples were immedi-
ately centrifuged at 4 C and deep frozen until analysis.
Part 2: effect of free fatty acids on neurotensin release
The design of the second series was similar to part 1: 12 healthymale
subjects swallowed a feeding tube,whichwas positioned in part III of the
duodenum under fluoroscopic control. The study was conducted in a
randomized, double-blind, three-period crossover fashion. All treat-
ments were given in the morning after an overnight fast. One treatment
consisted of ID infusion of medium chain fatty acids (C8s) in the form of
sodium caprylate. Sodium caprylate was perfused at a concentration of
0.049 g/ml at a rate of 0.5 ml/min, resulting in a load of 8mmol/h. In the
second experiment, long chain fatty acids (C18s) in the form of sodium
oleate were infused at a concentration of 0.086 g/ml at a rate of 0.5
ml/min, resulting in a load of 8 mmol/h. On the third experimental day,
volunteers received IDvehicle (control) insteadof free fatty acids.TheC8
andC18 loadswere chosen fromprevious experiments (19).During each
treatment, samples of bloodweredrawn (7.5ml each) at regular intervals
into EDTA coated tubes containing aprotinin (1000 kallikrein inhibiting
unit/ml blood) for plasma CCK and neurotensin determinations.
Part 3: effect of C18 with and without iv dexloxiglumide
(DEXLOX) on neurotensin secretion
The design of the third series was similar to part 2: healthy male
subjects swallowed a feeding tube,whichwas positioned in part III of the
duodenumunder fluoroscopic control. Three treatments, separatedby at
least 7 d, were performed after fasting overnight in 10 subjects in a
randomized order. Subjects received on 2 experimental days continuous
ID infusion of C18 (sodium oleate, 8 mmol/h, for a total of 120 min)
together with either an iv infusion of isotonic saline (control) or an in-
fusion of the CCK-1 receptor antagonist DEXLOX (5 mg/kgh) for the
duration of the study. The dose of DEXLOX was chosen from previous
experiments. Intravenous infusions were started 30 min before ID infu-
sion (19). On the third experimental day, subjects received ID saline and
iv saline during the study. Ambulatory infusion pumps through a Teflon
catheter (DuPont Co., Wilmington, DE) inserted into a forearm vein
delivered infusions. Blood was taken (7.5 ml) at regular intervals for
hormone determinations.
FIG. 2. Plasma concentrations of CCK (A) and neurotensin (B) during ID
infusions of C18 (sodium oleate, 8 mmol/h), C8 (sodium caprylate, 8 mmol/
h), or infusion of vehicle (control treatment) in 12 healthy male subjects.
C18 increased CCK and neurotensin levels progressively (P  0.01 each)
compared with controls. C8 did not affect hormone levels. Plasma CCK
and neurotensin concentrations were not different from control values.
Data are mean  SEM.
TABLE 2. Plasma pharmacokinetics of CCK and neurotensin during ID infusions of fat or vehicle (control treatment) with and
without orlistat in 12 healthy male subjects
Treatments
ID vehicle (control) ID fat alone ID fat plus Orlistat
CCK
AUC (0–120 min) (pmol/minliter) 115.4  4.18 (NA) 319.5  46.63 (P  0.001) 131.4  5.6 (NS)
Cmax (pmol/liter) 1.3  0.07 (NA) 3.9  0.63 (P  0.001) 1.4  0.11 (NS)
Tmax (min) 67.5  11.75 (NA) 105.0  7.83 (P  0.013) 67.5  7.5 (NS)
ID vehicle plus iv saline (control) ID TG plus iv saline ID TG plus iv Orlistat
Neurotensin
AUC (0–120 min) (pmol/minliter) 628.3  30.0 (NA) 1234.6  102.4 (P  0.001) 605.2  25.6 (NS)
Cmax (pmol/liter) 6.6  0.3 (NA) 16.1  1.6 (P  0.001) 6.2  0.2 (NS)
Tmax (min) 25.0  6.2 (NA) 85.0  6.3 (P  0.001) 65.0  15.6 (P  0.02)
Data are mean  SEM (n  12 per group). P values represent statistically significant differences vs. control. AUC, Area under the curve; NA, not applicable; NS,
nonsignificant; Cmax, maximum plasma concentration; Tmax, time at which plasma concentration is maximum.
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Plasma hormone determinations
Plasma CCK concentrations were measured using a sensitive RIA
based on an antiserum that recognizes the sulfated tyrosine residue of
CCK8 but has minor cross-reactivity with sulfated gastrin (1%) and
does not cross-react with unrelated gastrointestinal peptides (Table 1).
Synthetic, labeled CCK-8 was bought from Eurodiagnostica (Malmoe,
Sweden) and used as a tracer, and synthetic CCK-8 was used as a stan-
dard. Separation of free from antibody bound hormone was performed
by adsorption of the free peptide to charcoal [addition of 0.5 ml plasma-
assay buffer suspension, 1:4 (vol/vol), containing 16 mg charcoal]. The
sensitivity of the assay was 0.6 pmol/liter plasma.
Plasma samples were extracted with 96% (vol/vol) ethanol (1:2, vol/
vol). The recovery of CCK-33 added to charcoal-treated plasma before
the extraction procedure was more than 75%.
Neurotensin was measured with a commercially available kit (Phoe-
nix Europe GmbH, Karlsruhe, Germany). 125I-neurotensin was used as
a label; the labeled peptide was purified by HPLC (specific activity 302
Ci/g). The lowest level of neurotensin that could be detected by this
assay was 10 pg/ml when using a 100 l plasma sample. Intraassay and
interassay variabilities were less than 11% and less than 13%, respec-
tively. Plasma samples were extracted with C18-Sep-Pak (Millipore
Corp., Billerica, MA).
In a recent study, it was suggested that a reliable measurement of
matureneurotensin is difficult due to its instability and its rapid clearance
from the circulation with a half-life of 2–6 min, often leading to an
underestimation of the actual neurotensin levels (14, 21). The identifi-
cation of the more stable precursor peptide pro-NT/NMN, which is
produced in stoichiometric amounts to mature neurotensin, allowed us
to compare directly the twomolecular forms in plasma. Therefore, some
samples were also assayed for pro-NT/NMN. Pro-NT/NMN was mea-
sured byA. Ernst (SphingoTecGmbH,Borgsdorf,Germany) using a new
sandwich immunoassay as previously described (21). Briefly, pro-NT/
NMNwasmeasured ina sandwich immunoassayusingpolyclonal rabbit
antibodies against the pro-NT/NMN-peptides 44–62 and 98–117. An-
tibodies were purified from rabbit antisera by affinity chromatography.
Antibodies to amino acids 44–62 were coated on polystyrene tubes (2
g/tube) as solid phase, and antibodies to amino acids 98–117 were
labeledwithacridiniumester-N-hydroxy-succinimide for chemilumines-
cence detection. The assaywas calibrated using a human reference serum
pool. The analytical assay sensitivity as determined with normal horse
serum was 9.95 pmol/liter. Serum samples with pro-NT/NMN concen-
trations above the highest calibrator were pre-diluted in normal horse
serum, measured again, and the concentration was subsequently
extrapolated.
Statistical analysis
Hormoneparameterswere comparedamong treatment groupsby the
general linear model analysis using repeatedmeasurement option. If this
analysis revealed significant differences between the treatments, treat-
ment groups were compared with the control group by simple linear
contrasts. The level of significance was P 0.05. All statistical compar-
isons were performed using SPSS for Windows software (version 14.0;
SPSS, Inc., Chicago, IL).
Results
Part 1
Plasma neurotensin concentrations were significantly in-
creased with fat infusion (P 0.001) compared with the control
treatment (Fig. 1 and Table 2). Orlistat (60 mg, infused together
with fat) reversed the effects of ID fat. The stimulation of neu-
rotensin release was virtually blocked by the lipase inhibitor; as
a consequence, neurotensin concentrations were similar to con-
trols. These data indicate that fat induced increase in circulating
neurotensin can be abolished by inhibition of fat hydrolysis.
CCK measurements served as positive controls. As expected,
orlistat infusion markedly attenuated the fat induced increase in
circulating CCK (Fig. 1 and Table 2), thereby confirming pre-
vious results (19).
Part 2
Fasting hormone concentrations were comparable in the dif-
ferent treatments. During the control treatment and during in-
fusion of C8, plasma neurotensin and CCK levels remained
largelyunchanged. IDadministrationofC18causeda significant
increase in both plasma CCK and neurotensin levels (P 0.001
and P 0.001, respectively) compared with controls (Fig. 2 and
Table 3).
Part 3
ID infusion of C18 with iv infusion of saline caused a signif-
icant (P 0.001) increase in plasma neurotensin comparedwith
controls (Fig. 3 and Table 4). In contrast, ID C18 infusion to-
gether with iv DEXLOX resulted in a blunted neurotensin re-
sponse in the first 60 min compared with ID C18 plus iv saline
(P 0.003; Fig. 3 and Table 4). After 60min, neurotensin levels
markedly increased in response to C18 infusion together with iv
DEXLOX; the area under the curve for the time period 60–120
minwas higher forC18 infusion togetherwith ivDEXLOX (P
0.06) compared with ID C18 infusion plus iv saline (Table 4).
TABLE 3. Plasma pharmacokinetics of CCK and neurotensin during ID infusions of C18s, C8s, or infusion of vehicle (control
treatment) in 12 healthy male subjects
Treatments
ID saline (control) ID C8 ID C18
CCK
AUC (0–120 min) (pmol/minliter) 114.2  5.2 (NA) 113.1  3.8 (NS) 272.3  23.1 (P  0.001)
Cmax (pmol/liter) 1.1  0.1 (NA) 1.2  0.1 (NS) 3.3  0.3 (P  0.001)
Tmax (min) 48.0  11.1 (NA) 63.0  13.7 (NS) 93.0  11.4 (P  0.02)
Neurotensin
AUC (0–120 min) (pmol/minliter) 616.9  40.3 (NA) 754.9  93.5 (P  0.001) 1149.8  59.4 (P  0.001)
Cmax (pmol/liter) 6.1  0.4 (NA) 7.6  1.0 (P  0.0019) 12.7  1.1 (P  0.001)
Tmax (min) 45.0  12.0 (NA) 51.0  6.4 (NS) 66.0  6.0 (NS)
Data are mean  SEM (n  12 per group). P values represent statistically significant differences vs. control. AUC, Area under the curve; NA, not applicable; NS,
nonsignificant; Cmax, maximum plasma concentration; Tmax, time at which plasma concentration is maximum.
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These data indicate that the increase in plasma neurotensin con-
centrations induced by ID C18 administration can only be
blocked in part by the CCK-1 receptor antagonist DEXLOX.
The results suggest that circulating CCK via CCK-1 receptors
mediates the first phase of C18-stimulated neurotensin release.
As depicted in Fig. 3 and Table 4, ID infusion of C18 with iv
infusion of saline caused a significant increase in plasma CCK
compared with controls (ID saline plus iv saline). ID C18 infu-
sion together with iv DEXLOX resulted in a significantly aug-
mented CCK response (Fig. 3 and Table 4) in comparison to ID
C18 plus iv saline.
Pro-NT/NMN measurement
Figure 4 depicts the time course of pro-NT/NMN in response
to ID infusionofC18with iv infusionof salineor IDC18 infusion
togetherwith ivDEXLOX. The pattern of pro-NT/NMN is very
similar to the data obtained with mature neurotensin (Fig. 3),
suggesting that both assays were able to quantify reliably the
respective molecules.
Discussion
Neurotensin is a regulatory signal from the gastrointestinal tract
that can modulate digestive functions (8, 9, 11). Recently, it has
also been implicated in the regulation of appetite and food intake
(11, 14–16). Further understanding of the physiological mech-
anisms by which this hormone is stimulated by nutrients is re-
quired to appreciate the regulatory circuits controlling appetite
and food intake. Different macronutrients exert specific effects
on satiety signals. Fat, as an example, is one macronutrient that
has been shown before to stimulate CCK, GLP-1, PYY, and
neurotensin release (5, 17–19, 22–26). Here, we investigated the
importance of different digestion products of fat in regulating
neurotensin secretion.
Three different approaches were used to establish that fat
hydrolysis is a critical step in the control of neurotensin release.
First, we used the lipase inhibitor orlistat as a tool to assess the
importance of fat hydrolysis in initiating the release of neuro-
tensin. Stimulation of neurotensin release in response to intesti-
nal fat infusion was completely abolished by orlistat adminis-
tration.We infer from these data that fat-stimulated neurotensin
release is dependent on adequate fat hydrolysis. The present re-
sults extend the list of digestive functions, which are dependent
on adequate fat hydrolysis.
In a second step, we analyzed the importance of the chain
length of fatty acids in triggering neurotensin release. In this part
of the study,C8s in the formof sodiumcaprylate containing eight
carbons (denominated C8) or C18s in the form of sodium oleate
with 18 carbons (denominated C18) were infused into the small
intestine. C18 infusion resulted in a marked increase in neuro-
tensin andCCK concentrations. C8 infusion did not change neu-
rotensin concentrations. These observations suggest that in ad-
dition to fat hydrolysis, the chain length of free fatty acids is
crucial for initiatingneurotensin secretion. Jonkers et al. (25)had
previously compared long chain triglycerides to very long chain
triglycerides and saline perfusion, and concluded that CCK re-
lease and gallbladder contraction was chain length dependent,
whereas neurotensin release and small bowel transit were chain
length independent. These data were in part confirmed and ex-
tended by the present results.
In the third part, we used the specific CCK-1 receptor antag-
onistDEXLOXtoblock the actions ofCCK.TheC18 stimulated
neurotensin responsewaspartiallyblockedwithCCK-1 receptor
blockade, suggesting that the first phase of neurotensin secretion
stimulated by intestinal fat was mediated by CCK via its CCK-1
receptor. The stimulation of this first phase of neurotensin se-
cretion is mediated either hormonally through circulating CCK
or neurally via CCK-containing nerves because it is not possible
that luminal fat has reached the distal small intestine to directly
stimulate neurotensin release at this stage. In a second phase, a
direct stimulation of neurotensin secreting cells through luminal
FIG. 3. Effect of DEXLOX, a specific CCK-1 receptor antagonist, on plasma
concentrations of CCK (A) and neurotensin (B) during ID infusions of C18s
or infusion of vehicle (control treatment) in 10 healthy male subjects. C18
increased CCK and neurotensin concentrations progressively (P  0.01
each). Intravenous administration of DEXLOX (5 mg/kgh) partially
antagonized the effects induced by intraluminal fat. Plasma neurotensin
concentrations were not different from control values in the first 60 min
but increased progressively thereafter. Data are mean  SEM.
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C18 is, however, possible. Fromtheseobservations the following
concept canbedeveloped.Adequate fat hydrolysis is required for
stimulatingneurotensin release; in the first phase, theproducts of
fat digestion stimulate CCK release, which in turn regulates neu-
rotensin secretion via CCK-1 receptors. At this stage it cannot be
determined whether circulating CCK is responsible for inducing
these effects; it is also conceivable that direct activationofCCK-1
receptors on afferent vagal fibers through C18 stimulation is a
potential pathway. After about 60 min, the CCK-1 receptor an-
tagonist was unable to suppress neurotensin release, suggesting
that a direct stimulation of the neurotensin cell has occurred
through C18s. The receptor and the molecular mechanisms me-
diating this effect need to be elaborated. Schmidt et al. (24) have
previously reported on the effects of loxiglumide on neurotensin
secretion stimulated with a test meal; no effect on neurotensin
release was observed under these conditions. There are several
possibilities for these discrepant findings: 1) experimental design
(oral test meal administration vs. duodenal perfusion of fat), 2)
confounding effects of oral meal intake (CCK-1 receptor block-
ade can accelerate gastric emptying), 3) potency of CCK-1 re-
ceptor antagonist (DEXLOXismorepotent than loxiglumideon
amolar basis), and 4) type of stimulant (C18 vs. meal). The exact
mechanism needs to be established.
The clinical implications of these findings relate to patients
who have undergone gastric bypass surgery for obesity. Changes
in gastrointestinal peptide concentrations have been reported for
GLP-1, PYY, and neurotensin after bariatric surgery (14, 15).
The increased levels of these three peptides after bypass surgery
have been used to explain the decreased appetite and energy
intake after the surgical procedures despite weight loss, which
undernormal conditionswould induce compensatoryhyperpha-
gia. However, a role for neurotensin in regulating appetite has
not been established and requires further investigation.
The measurement of mature neurotensin has been difficult;
the reasons that have been listed include its instability and its
rapid clearance from the circulation with a short half-life, some-
times leading to an underestimation of the actual neurotensin
levels (21). Measuring the more stable precursor pro-NT/NMN
provides an alternative tool to quantify neurotensin levels in
clinical practice. Thepresent data reveal thatmature neurotensin
concentrations can be adequately measured if standard precau-
tions are used, such as blood drawing into ice-chilled EDTA
tubes containing aprotinin and immediate centrifugation at 4 C.
The pattern of neurotensin release was similar to the pattern of
pro-NT/NMN, and no significant differenceswere documented.
The advantage of measuring pro-NT/NMN is probably outside
the research setting in daily clinical practice, where the standard
precautions stated previously are difficult to follow.
In summary, three pertinent conclusions can be drawn from
the present study: 1) adequate fat digestion is crucial for stimu-
lating plasma neurotensin secretion, 2) C18s are necessary to
initiate the release of neurotensin, and 3) CCK-1 receptor block-
ade attenuates the first phase of neurotensin secretion but does
not affect the second phase of neurotensin release. The data sup-
port the following conclusions: fat hydrolysis in the proximal
small intestine is required to start the process; the specific prod-
ucts of fat digestion, C18s, then stimulate the release of CCK
(neural or hormonal); andCCK in turn acts onCCK-1 receptors,
which then initiates the release of neurotensin secretion. If hy-
FIG. 4. Effect of iv DEXLOX or saline on plasma concentrations of pro-NT/
NMN during ID infusions of C18s in 10 healthy male subjects. C18 induced
a progressive increase in pro-NT/NMN concentrations (P  0.01).
Intravenous administration of DEXLOX (5 mg/kgh) partially antagonized
the effects induced by intraluminal fat. Plasma pro-NT/NMN
concentrations were suppressed in the first 60 min but increased steadily
thereafter. Data are mean  SEM.
TABLE 4. Plasma pharmacokinetics of CCK and neurotensin during ID infusions of C18 or infusion of vehicle (control treatment)
with and without iv DEXLOX in 10 healthy male subjects
Treatments
ID vehicle plus iv saline
(control) (A) ID C18 plus iv saline (B) ID C18 plus iv DEXLOX (C)
CCK
AUC (0–120min) (pmol/minliter) 164.0 12.5(NA) 277.4  31.5 (NS) 1073.2  138.8 P 0.001 vs. (A) P 0.001 vs. (B)
Cmax (pmol/liter) 2.1 0.3 (NA) 3.6  0.5 (NS) 14.7  1.5 P 0.001 vs. (A) P 0.001 vs. (B)
Tmax (min) 54.0 14.0(NA) 81.0  11.9 (NS) 96.0  6.0 (P 0.033)
Neurotensin
AUC (0–120min) (pmol/minliter) 419.0 52.8(NA) 768.8  83.4 (P 0.001) 823.6  54.9 (P 0.002)
AUC (0–60min) (pmol/minliter) 236.9 25.3(NA) 440.8  64.4 P 0.015, vs. control (A) 316.1  45.6 (NS) vs. control (A)
AUC (60–120min) (pmol/minliter) 182.1 29.8(NA) 328.0  22.2 P 0.003, vs. control (A) 507.5  31.4 P 0.001, vs. control (A) P 0.001, vs. (B)
Cmax (pmol/liter) 5.1 0.7 (NA) 9.2  1.3 P 0.001, vs. control (A) 11.7  0.9 P 0.002, vs. control (A)
Tmax (min) 12.0 6.2 (NA) 52.5  10.3 P 0.01, vs. control (A) 90.0  13.4 P 0.001, vs. control (A)
P values represent statistically significant differences vs. the respective treatment (ANOVA, Scheffe’s multicomparison test). Data are mean  SEM (n  10 per group).
AUC, Area under the curve; NA, not applicable; NS, nonsignificant; Cmax, maximum plasma concentration; Tmax, time at which plasma concentration is maximum.
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drolyzed fatty acids reach the distal small intestine, a direct stim-
ulation of neurotensin occurs through C18s.
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